Patents by Inventor James Jaquith

James Jaquith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein kinase inhibitors
    Patent number: 9624239
    Abstract: The present invention relates to a novel family of inhibitors of protein kinases of Formula (1) wherein X is selected from CH2, O, S(0)n, or NR6; and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src, Btk and Lck protein kinase families.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: April 18, 2017
    Assignee: Pharmascience Inc.
    Inventors: Alain Laurent, Yannick Rose, Stephen Morris, James Jaquith
  • IAP BIR domain binding compounds
    Patent number: 9365614
    Abstract: A compound of Formula I or a salt thereof, methods for the preparation thereof, and related methods and compositions.
    Type: Grant
    Filed: May 23, 2014
    Date of Patent: June 14, 2016
    Assignee: Pharmascience Inc.
    Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
  • Protein kinase inhibitors
    Patent number: 9284318
    Abstract: The present invention relates to novel kinase inhibitors. Compounds of this class have been found to be effective inhibitors of protein kinases, including members of PDGFR and VEGFR families.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: March 15, 2016
    Assignee: Pharmascience, Inc.
    Inventors: Alain Laurent, Yannick Rose, Stephen Morris, James Jaquith
  • PROTEIN KINASE INHIBITORS
    Publication number: 20150210696
    Abstract: The present invention relates to novel kinase inhibitors. Compounds of this class have been found to be effective inhibitors of protein kinases; including members of PDGFR and VEGFR families.
    Type: Application
    Filed: April 3, 2012
    Publication date: July 30, 2015
    Inventors: Alain Laurent, Yannick Rose, Stephen Morris, James Jaquith
  • IAP BIR Domain Binding Compounds
    Publication number: 20140336134
    Abstract: A compound of Formula I or a salt thereof, methods for the preparation thereof, and related methods and compositions.
    Type: Application
    Filed: May 23, 2014
    Publication date: November 13, 2014
    Applicant: Pharmascience Inc.
    Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
  • IAP BIR domain binding compounds
    Patent number: 8765681
    Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.
    Type: Grant
    Filed: November 8, 2012
    Date of Patent: July 1, 2014
    Assignee: Pharmascience Inc.
    Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
  • Protein Kinase Inhibitors
    Publication number: 20140045833
    Abstract: The present invention relates to a novel family of inhibitors of protein kinases of Formula (1) wherein X is selected from CH2, O, S(0)n, or NR6; and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src, Btk and Lck protein kinase families.
    Type: Application
    Filed: April 3, 2012
    Publication date: February 13, 2014
    Applicant: PHARMASCIENCE INC.
    Inventors: Alain Laurent, Yannick Rose, Stephen Morris, James Jaquith
  • IAP BIR domain binding compounds
    Patent number: 8648094
    Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: February 11, 2014
    Assignee: Pharmascience, Inc.
    Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
  • IAP BIR domain binding compounds
    Publication number: 20120195915
    Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.
    Type: Application
    Filed: March 21, 2012
    Publication date: August 2, 2012
    Applicant: PHARMASCIENCE INC.
    Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
  • IAP BIR domain binding compounds
    Patent number: 8163792
    Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.
    Type: Grant
    Filed: May 16, 2007
    Date of Patent: April 24, 2012
    Assignee: Pharmascience Inc.
    Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
  • IAP BIR domain binding compounds
    Patent number: 8063095
    Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: November 22, 2011
    Assignee: Pharmascience Inc.
    Inventors: Alain Laurent, Kim Hewitt, Stephen Morris, Patrick Bureau, Alain Boudreault, Scott Jarvis, James Jaquith
  • IAP BIR DOMAIN BINDING COMPOUNDS
    Publication number: 20110177060
    Abstract: IAP BIR domain binding compounds of Formula (I), (II), (III), or (IV), and the use thereof, for example, for the treatment or prevention of proliferative diseases.
    Type: Application
    Filed: September 17, 2009
    Publication date: July 21, 2011
    Applicant: AEGERA THERAPEUTICS, INC.
    Inventor: James Jaquith
  • FUNCTIONALIZED PYRROLIDINES AND USE THEREOF AS IAP INHIBITORS
    Publication number: 20110117081
    Abstract: A compound of Formula (1) or a salt thereof, methods for the preparation and use of such a compound, especially as an IAP inhibitor, and related compounds, compositions, and methods.
    Type: Application
    Filed: May 5, 2009
    Publication date: May 19, 2011
    Applicant: Aegera Therapeutics, Inc.
    Inventors: Alain Laurent, Melanie Proulx, James Jaquith
  • BIR DOMAIN BINDING COMPOUNDS
    Publication number: 20100292269
    Abstract: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains.
    Type: Application
    Filed: June 28, 2010
    Publication date: November 18, 2010
    Applicant: AEGERA THERAPEUTICS, INC.
    Inventors: Scott Jarvis, Alain Boudreault, Patrick Bureau, James Jaquith, Alain Laurent, Delphine Labit
  • IAP BIR domain binding compounds
    Patent number: 7795298
    Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
    Type: Grant
    Filed: December 4, 2006
    Date of Patent: September 14, 2010
    Assignee: Aegera Therapeutics, Inc.
    Inventors: Alain Laurent, Kim Hewitt, Stephen Morris, Patrick Bureau, Alain Boudreault, Scott Jarvis, James Jaquith
  • IAP BIR DOMAIN BINDING COMPOUNDS
    Publication number: 20100221261
    Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.
    Type: Application
    Filed: November 17, 2009
    Publication date: September 2, 2010
    Applicant: Aegera Therapeutics, Inc.
    Inventors: Alain Boudreault, James Jaquith, Patrick Bureau, John W. Gillard, Alain Laurent
  • IAP BIR DOMAIN BINDING COMPOUNDS
    Publication number: 20100203012
    Abstract: Disclosed herein is a compound of Formula 1: or a salt thereof, in which R1, R1a, R100, R100a, R2, R200, R3, R300, A, A1, Q, Q1 and BG are as defined herein. Also disclosed is the use of the compounds of Formula 1 to treat disorders of dysregulated apoptosis, such as cancer and cellular proliferative disorders.
    Type: Application
    Filed: May 30, 2008
    Publication date: August 12, 2010
    Applicant: Aegera Therapeutics, Inc.
    Inventors: Alain Laurent, Patrick Bureau, James Jaquith, John Gillard, Yannick Rose
  • BIR domain binding compounds
    Patent number: 7772177
    Abstract: The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer.
    Type: Grant
    Filed: May 16, 2006
    Date of Patent: August 10, 2010
    Assignee: Aegera Therapeutics, Inc.
    Inventors: Scott Jarvis, Alain Boudreault, Patrick Bureau, James Jaquith, Alain Laurent, Delphine Labit
  • IAP BIR DOMAIN BINDING COMPOUNDS
    Publication number: 20090192140
    Abstract: Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.
    Type: Application
    Filed: May 16, 2007
    Publication date: July 30, 2009
    Applicant: Aegera Therapeutics Inc.
    Inventors: Alain Laurent, Scott Jarvis, Patrick Bureau, Alain Boudreault, James Jaquith
  • IAP BIR domain binding compounds
    Patent number: 7547724
    Abstract: Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
    Type: Grant
    Filed: December 1, 2006
    Date of Patent: June 16, 2009
    Assignee: Aegera Therpeutics, Inc.
    Inventors: Alain Laurent, Kim E. Hewitt, Stephen Morris, Patrick Bureau, Alain Boudreault, Scott Jarvis, James Jaquith